Sysmex (OTCMKTS:SSMXY) Updates FY 2026 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) issued an update on its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.382-0.382 for the period, compared to the consensus earnings per share estimate of 0.440. The company issued revenue guidance of $3.4 billion-$3.4 billion, compared to the consensus revenue estimate of $3.1 billion.

Sysmex Stock Performance

OTCMKTS SSMXY opened at $10.94 on Friday. The company’s 50 day simple moving average is $9.38 and its two-hundred day simple moving average is $9.08. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46. Sysmex has a 1 year low of $8.01 and a 1 year high of $14.20. The stock has a market capitalization of $6.89 billion, a PE ratio of 26.05 and a beta of 1.05.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings results on Friday, August 7th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. The firm had revenue of $825.85 million during the quarter, compared to analyst estimates of $739.25 million. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Analysts predict that Sysmex will post 0.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut Sysmex from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.